Schroder Investment Management Group Reduces Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Schroder Investment Management Group reduced its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 19.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 743,230 shares of the biopharmaceutical company’s stock after selling 180,941 shares during the period. Schroder Investment Management Group owned 0.70% of Intra-Cellular Therapies worth $62,045,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ITCI. True Wealth Design LLC purchased a new position in shares of Intra-Cellular Therapies in the third quarter worth about $32,000. GAMMA Investing LLC grew its stake in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 240 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Intra-Cellular Therapies during the 4th quarter valued at $96,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth $97,000. Finally, Quarry LP boosted its holdings in shares of Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 1,300 shares during the period. 92.33% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Price Performance

NASDAQ:ITCI opened at $131.92 on Tuesday. The company has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.63 and a beta of 0.69. The business has a 50 day moving average of $129.23 and a 200 day moving average of $100.20. Intra-Cellular Therapies, Inc. has a 1-year low of $64.09 and a 1-year high of $131.95.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. As a group, sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Analyst Ratings Changes

ITCI has been the topic of a number of analyst reports. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Mizuho downgraded shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $140.00 to $132.00 in a report on Monday, February 24th. StockNews.com started coverage on shares of Intra-Cellular Therapies in a research note on Friday. They set a “hold” rating for the company. Piper Sandler reiterated a “neutral” rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Ten analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $106.08.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.